Navigation Links
'Flipping the switch' reveals new compounds with antibiotic potential
Date:10/31/2013

CORVALLIS, Ore. Researchers at Oregon State University have discovered that one gene in a common fungus acts as a master regulator, and deleting it has opened access to a wealth of new compounds that have never before been studied with the potential to identify new antibiotics.

The finding was announced today in the journal PLOS Genetics, in research supported by the National Institutes of Health and the American Cancer Society.

Scientists succeeded in flipping a genetic switch that had silenced more than 2,000 genes in this fungus, the cereal pathogen Fusarium graminearum. Until now this had kept it from producing novel compounds that may have useful properties, particularly for use in medicine but also perhaps in agriculture, industry, or biofuel production.

"About a third of the genome of many fungi has always been silent in the laboratory," said Michael Freitag, an associate professor of biochemistry and biophysics in the OSU College of Science. "Many fungi have antibacterial properties. It was no accident that penicillin was discovered from a fungus, and the genes for these compounds are usually in the silent regions of genomes.

"What we haven't been able to do is turn on more of the genome of these fungi, see the full range of compounds that could be produced by expression of their genes," he said. "Our finding should open the door to the study of dozens of new compounds, and we'll probably see some biochemistry we've never seen before."

In the past, the search for new antibiotics was usually done by changing the environment in which a fungus or other life form grew, and see if those changes generated the formation of a compound with antibiotic properties.

"The problem is, with the approaches of the past we've already found most of the low-hanging fruit, and that's why we've had to search in places like deep sea vents or corals to find anything new," Freitag said. "With traditional appr
'/>"/>

Contact: Michael Freitag
freitagm@science.oregonstate.edu
541-737-4845
Oregon State University
Source:Eurekalert  

Page: 1 2

Related biology technology :

1. An optical switch based on a single nano-diamond
2. Netswitch Technology Management Ranks in Top 100 Cloud and Managed Service Providers
3. Save Space with Scienceware® Switch-Grid™ Test Tube Racks by Bel-Art Products
4. Cornell bioengineers discover the natural switch that controls spread of breast cancer cells
5. Penn researchers make first all-optical nanowire switch
6. Millions of DNA switches that power human genomes operating system are discovered
7. Metamolecules that switch handedness at light-speed
8. Switchable nano magnets
9. Reversible doping: Hydrogen flips switch on vanadium oxide
10. The smallest conceivable switch
11. Find The Black Box Reveals how Troubled Doctors Have Found a Haven in Texas
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Flipping the switch' reveals new compounds with antibiotic potential
(Date:2/26/2015)... LAUDERDALE, Fla. , Feb. 26, 2015 ... discussed growth priorities driven by key research advancements and ... segments at today,s Bank of America Merrill Lynch 2015 ... met the challenge of building grain supplies the last ... to continue at the pace of the last decade, ...
(Date:2/26/2015)... 2015 The healthcare landscape is rapidly and radically ... Sullivan will host its 20 th Anniversary Medical ... 8 to 10, at the Hilton San Diego Resort and ... This event is a platform for global medical devices, ... disruptions and how to succeed in an uncertain future. ...
(Date:2/26/2015)... Innovation is more urgent than ever. Radical ... the world and transforming global markets in industry ... health care, disruption is constantly underway. , As ... shake the foundations of established business models, large-scale ... survive the next wave of mega-change. , This ...
(Date:2/26/2015)... February 26, 2015 Regis Technologies ... development of oncology drug substances. , Regis Technologies is ... their new Potent Compound Suite (PCS) for 2015. , ... square foot, cGMP facility in Morton Grove, Illinois. The ... of potent compounds up to about one kilogram per ...
Breaking Biology Technology:DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Regis Extends cGMP Services to Oncology Market 2
... Trial in Medullary Thyroid Cancer Planned to Initiate ... 16 ,Exelixis, Inc. (Nasdaq: EXEL ) announced ... Drug Administration (FDA) have reached agreement on the ... anticancer compound targeting,MET, RET, and VEGFR2, via the ...
... Thermage Inc. To, Drive Coapt,s Growth In ... June 13 Coapt Systems, Inc.,developer of bioabsorbable implants ... and sports medicine markets, announced today the,appointment of Laureen ... as a member of the company,s Board of Directors. ...
... landmark IRIS trial, which established Gleevec as standard ... of care, - Study did not ... molecular responses with 800 vs. 400 ... optimize treatment benefit for individual ...
Cached Biology Technology:Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 2Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 3Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 4Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 5Coapt Systems New CEO, Laureen DeBuono, to Fuel Company's Growth and Product Innovation 2Coapt Systems New CEO, Laureen DeBuono, to Fuel Company's Growth and Product Innovation 3Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 2Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 3Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 4Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 6Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 7Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 8Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 9Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 10Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 11Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 12Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 13
(Date:1/22/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a ... the recent success of the Wocket™ smart wallet at CES 2015 in ... was named as one of the "11 Hot Products at CES" in ... At CES So Far" by Newseveryday.com and "The top 10 gadgets from ...
(Date:1/22/2015)... , January 22, 2015 , ... year  The European Patent Office to present a video ... British nominations to be featured: Christofer Toumazou and ... former finalists and winners of the Award   Starting ...
(Date:1/22/2015)... has launched its new NXG series of time clocks with ... higher standard for collecting attendance and labor data and complements ... touch screen interface and seamless connection to cloud-based iSolved, the ... for the small to mid-size employer. The G2 ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3Infinisource's NXG series sets new time clock standard 2
... researchers have identified the neurocircuit that controls the brain's ... be possible to understand psychiatric disorders, such as anxiety ... brain. , They accomplished this using an adapted version ... that enables analysis of function in the brain. , ...
... the January/February 2007 issue of Physiological and Biochemical Zoology, ... may respond to water diversion and climate change. Endangered ... spawn, and a lake in Western China, where they ... and becoming increasingly more saline--leading to surprising adjustments to ...
... blood oxygen levels of a baby during labor--expected to ... benefit, report researchers in a National Institutes of Health ... saturation monitoring, was designed for use along with electronic ... measure changes in fetal oxygen levels. Designers of ...
Cached Biology News:Emotional control circuit of brain's fear response discovered 2Emotional control circuit of brain's fear response discovered 3Climate change has surprising effect on endangered naked carp 2Technology for monitoring fetal oxygen during labor offers no apparent benefit 2Technology for monitoring fetal oxygen during labor offers no apparent benefit 3
Request Info...
Mouse Galectin-1 Affinity Purified Polyclonal Ab...
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Mouse monoclonal [MLM544] to cardiac Myosin light chain 1 ( Abpromise for all tested applications). entrezGeneID: 4634 SwissProtID: P08590...
Biology Products: